This article was originally published in The Gray Sheet
Submits premarket approval application Oct. 3 for the in vitro diagnostic use of its chronic myelogenous leukemia (CML) Mbcr/abl genetic test system. The company says that in multi-center trials involving close to 350 patients, the Oncor test, when used alone, "was 96.1% sensitive and 99.3% specific in detecting CML, compared to the detection rates of a combination of the best presently available methods." The Gaithersburg, Maryland-based firm estimates that its test will cost "five times less than conventional methods"
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.